Vivos Therapeutics (VVOS) Non-Current Assets (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Non-Current Assets data on file, last reported at $20.2 million in Q1 2026.

• Quarterly Non-Current Assets rose 163.5% year-over-year to $20.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.2 million (up 155.07% YoY) and the FY2025 annual result came in at $20.8 million, up 165.88% from the prior year.
• Non-Current Assets declined to $20.2 million in Q1 2026 per VVOS's latest filing, from $20.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $20.8 million in Q4 2025 and bottomed at $7.7 million in Q1 2025.
• The 5-year median for Non-Current Assets is $8.3 million (2023), against an average of $11.0 million.
• Peak annual rise in Non-Current Assets reached 165.88% in 2025, while the deepest fall reached 6.32% in 2025.
• Tracing VVOS's Non-Current Assets over 5 years: stood at $8.3 million in 2022, then slipped by 0.33% to $8.3 million in 2023, then decreased by 5.54% to $7.8 million in 2024, then jumped by 165.88% to $20.8 million in 2025, then dropped by 2.62% to $20.2 million in 2026.
• Per Business Quant, the three latest VVOS Non-Current Assets figures stand at $20.2 million (Q1 2026), $20.8 million (Q4 2025), and $19.9 million (Q3 2025).

Peer Comparison